Prolight Diagnostics announces today that the Japan Patent Office, JPO has issued an official Decision to Grant notification for a second patent application relating to the Psyros single-molecule-counting technology. The official legal notification was dated the 24th of April 2026.
“Securing a second patent in Japan represents an important milestone and further strengthens our intellectual property position in a strategically important market. The patent demonstrates the versatility of the Psyros technology as a platform that can be adapted to many test types”, said Ulf Bladin, CEO of Prolight.
This second patent application in Japan expands the scope of the core Psyros technology and has particular utility for carrying out swab tests for infectious disease, such as flu, RSV or COVID. The patent describes the use of deuterated reagents to amplify signal generation and reduce the complexity and cost of the instrumentation. Access to rapid, extremely sensitive, low-cost tests for infectious disease is an important area for future growth of the technology.
A number of formalities will now take place before the process is complete, and the patent is fully granted and given an official number by the JPO.
Prolight currently have six families of patent applications relating to the Psyros technology being prosecuted in a range of worldwide territories. Three are granted in Europe, this will be the second in Japan, and it is expected by the company that several more will be granted in other countries in 2026.
